Results 341 to 350 of about 3,028,209 (373)
Some of the next articles are maybe not open access.
Controlling Off-Label Medication Use
Annals of Internal Medicine, 2009Off-label prescribing may lead to innovative new uses of old medications, is essential in such fields as pediatrics, and avoids the lengthy and expensive process of modifying U.S. Food and Drug Administration (FDA) drug labeling. Using medications for unapproved indications, however, raises concerns about patient safety when the drugs have a high ...
openaire +2 more sources
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders
Journal of Cutaneous Medicine and Surgery, 2019Off-label prescribing is a common practice in dermatology, particularly when uncommon dermatologic diseases have limited or no approved treatment options.
L. Guenther, C. Lynde, Y. Poulin
semanticscholar +1 more source
Current Drug Safety, 2018
BACKGROUND Given the growing use of off-label in pediatric practice, there is a growing interest on pharmacovigilance programs monitoring the occurrence of adverse drug reactions related to off-label drug prescription in childhood.
A. Praticò +22 more
semanticscholar +1 more source
BACKGROUND Given the growing use of off-label in pediatric practice, there is a growing interest on pharmacovigilance programs monitoring the occurrence of adverse drug reactions related to off-label drug prescription in childhood.
A. Praticò +22 more
semanticscholar +1 more source
[Off-label use of infliximab].
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2013Tumor necrosis factor α (TNFα) is a pro-inflammatory cytokine and a key mediator of inflammation. Several TNFα antagonists have been used therapeutically. One of them, infliximab, is a chimeric monoclonal antibody with anti-TNFα activity. Numerous studies have shown TNFα antagonists to be effective in treating psoriasis--particularly severe resistant ...
Onder, M., Fritz, K., Salavastru, C.
openaire +2 more sources
You can’t use this app for that: Exploring off-label use through an investigation of Tinder
The Information Society, 2019This article reconceptualizes the pharmacological term “off-label use” in the context of platforms and apps. It combines literature on technological appropriation with research on platforms’ sociotechnical arrangements to understand off-label use as ...
Stefanie Duguay
semanticscholar +1 more source
Off-label use of drugs in pediatrics: a scoping review
European Journal of Pediatrics, 2022M. Meng +15 more
semanticscholar +1 more source
Journal of Personality Disorders, 2019
The guidelines for borderline personality disorder (BPD) treatment suggest non-pharmacological treatment as the first option, but second-generation antipsychotics (SGAs) are among the overprescribed medications.
A. Aguglia +12 more
semanticscholar +1 more source
The guidelines for borderline personality disorder (BPD) treatment suggest non-pharmacological treatment as the first option, but second-generation antipsychotics (SGAs) are among the overprescribed medications.
A. Aguglia +12 more
semanticscholar +1 more source
„Off-label-use“ von Arzneimitteln
2008Das Arzneimittelrecht gehort zu den rechtlich am intensivsten regulierten Bereichen des Gesundheitswesens. Nicht zuletzt als Folge spektakularer Arzneimittelzwischenfalle („Contergan“) hat sich auf nationaler und europaischer Ebene ein umfassendes Regelwerk herausgebildet, das die Herstellung, das Inverkehrbringen und die Uberwachung von Arzneimitteln ...
openaire +2 more sources
Off-Label Use of Clozapine in Children and Adolescents—A Literature Review
American Journal of Therapeutics, 2019Background: Clozapine is a second-generation antipsychotic typically used for refractory schizophrenia or otherwise psychotic pathology. There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. We investigated the current
Vivekananda Rachamallu +3 more
semanticscholar +1 more source
Food and drug law journal, 2009
In this study, the authors examine factors underlying payer off-label use reimbursement policies. Updating a study published 14 years ago, presenting the results of the survey of 179 payers administering public (Medicare and Medicaid) pharmacy benefits.
Joshua, Cohen +2 more
openaire +1 more source
In this study, the authors examine factors underlying payer off-label use reimbursement policies. Updating a study published 14 years ago, presenting the results of the survey of 179 payers administering public (Medicare and Medicaid) pharmacy benefits.
Joshua, Cohen +2 more
openaire +1 more source